Skip to main content
. 2021 May 13;11:10166. doi: 10.1038/s41598-021-89620-7

Figure 4.

Figure 4

Relative risks of MACE, calculated in the network meta-analysis. Relative risks of MACE in participants (A) with obesity and (B) without obesity. SGLT-2, sodium-glucose cotransporter 2; GLP-1 RA, glucagon-like peptide-1 receptor agonist; MACE, major adverse cardiovascular events.